Session 1: Pathogenesis

Lead discussant: Yehuda Chowers, Haifa, Israel

Exposome

Genetics

Inflammatory pathways

Session 2: Part I: Case-based management of IBD therapies

Lead discussant: Peter Irving, London, United Kingdom

5-ASA compounds

Thiopurines

Methotrexate

Steroids

Anti-TNF agentes

Anti-integrines

Session 2: Part II: New biologics and small molecules

Lead discussant: Axel Dignass, Frankfurt, Germany

Ustekinumab

Tofacitinib

Other small molecules (apremilast/ozanimod)